Exchange: NASDAQ·Updated 04:50 AM EDT
News
all
press releases
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.
Zacks
More News
PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Zacks
Futures Hit Record High As Oil Tumbles After Bessent Says Hormuz May "Reopen Tomorrow"
Futures Hit Record High As Oil Tumbles After Bessent Says Hormuz May "Reopen Tomorrow" S&P futures are trading at all time high with the latest push higher triggered by comments from Scott Bessent on CNBC who echoed Trump in saying that "we may have Iran deal tomorrow to open Hormuz...
Zero Hedge
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, Pfizer) and BioNTech SE (Nasdaq: BNTX, BioNTech) announced today that the European Commission (EC) has granted marketing authorization for the companies 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by...
Business Wire
Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?
Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.
Zacks
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Pfizer's non-oncology portfolio faced mixed Q2 trends. Eliquis and Vyndaqel sales may have risen while COVID products will have declined.
Zacks
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.
Stocktwits
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.
Zacks
The New Cancer Moonshot: Innovative Companies Pursuing Game-Changing Therapies
Cancer treatment is undergoing one of the most significant transformations in modern medical history.
24-7 Market News
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks

Advertisement|Remove ads.